These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 31581028)

  • 1. The treatment efficacy of galcanezumab for migraine: A meta-analysis of randomized controlled trials.
    Ren Z; Zhang H; Wang R; Yuan Q; Pan L; Chen C
    Clin Neurol Neurosurg; 2019 Nov; 186():105428. PubMed ID: 31581028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials.
    Yang Y; Wang Z; Gao B; Xuan H; Zhu Y; Chen Z; Wang Z
    J Headache Pain; 2020 Feb; 21(1):14. PubMed ID: 32046655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Sexson M; Govindan S; Pearlman EM; Wang SJ; Khan A; Aurora SK
    Cephalalgia; 2019 Jul; 39(8):931-944. PubMed ID: 31104507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
    Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
    Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials.
    Stauffer VL; Turner I; Kemmer P; Kielbasa W; Day K; Port M; Quinlan T; Camporeale A
    J Headache Pain; 2020 Jun; 21(1):79. PubMed ID: 32576229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments.
    Kuruppu DK; Tobin J; Dong Y; Aurora SK; Yunes-Medina L; Green AL
    BMC Neurol; 2021 Apr; 21(1):175. PubMed ID: 33892641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials.
    Stauffer VL; Wang S; Voulgaropoulos M; Skljarevski V; Kovacik A; Aurora SK
    Headache; 2019 Jun; 59(6):834-847. PubMed ID: 30942898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies.
    Bangs ME; Kudrow D; Wang S; Oakes TM; Terwindt GM; Magis D; Yunes-Medina L; Stauffer VL
    BMC Neurol; 2020 Jan; 20(1):25. PubMed ID: 31952501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of galcanezumab for migraine: evidences from direct and indirect comparisons.
    Wang X; Song J; You C
    Int J Neurosci; 2023 Dec; 133(8):925-933. PubMed ID: 35815440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.
    Detke HC; Goadsby PJ; Wang S; Friedman DI; Selzler KJ; Aurora SK
    Neurology; 2018 Dec; 91(24):e2211-e2221. PubMed ID: 30446596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Efficacy of Vitamin D Supplementation for Migraine: A Meta-Analysis of Randomized Controlled Studies.
    Zhang YF; Xu ZQ; Zhou HJ; Liu YZ; Jiang XJ
    Clin Neuropharmacol; 2021 Jan-Feb 01; 44(1):5-8. PubMed ID: 33449474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Stauffer VL; Govindan S; Aurora SK; Terwindt GM; Goadsby PJ
    Eur J Neurol; 2020 Apr; 27(4):609-618. PubMed ID: 31692188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis.
    Zhao X; Xu X; Li Q
    J Neurol; 2021 Jul; 268(7):2364-2376. PubMed ID: 32006159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies.
    Smitherman TA; Tietjen GE; Schuh K; Skljarevski V; Lipsius S; D'Souza DN; Pearlman EM
    Headache; 2020 Nov; 60(10):2202-2219. PubMed ID: 33063862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).
    Silberstein SD; Stauffer VL; Day KA; Lipsius S; Wilson MC
    J Headache Pain; 2019 Jun; 20(1):75. PubMed ID: 31253091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.
    Ayer DW; Skljarevski V; Ford JH; Nyhuis AW; Lipton RB; Aurora SK
    Headache; 2018 Sep; 58(8):1225-1235. PubMed ID: 30106172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine.
    Popoff E; Johnston K; Croop R; Thiry A; Harris L; Powell L; Coric V; L'Italien G; Moren J
    Headache; 2021 Jun; 61(6):906-915. PubMed ID: 34021585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Efficacy and Safety of DFN-15 for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies.
    Deng Y; Chen Y; Peng Z; Yang H
    Clin Neuropharmacol; 2020; 43(4):107-111. PubMed ID: 32658036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.